InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $174.89M
• Dividend Yield: N/A
• Average Volume (3M): 111.09K
• Price to Earnings (P/E): 33.6
• Beta (1Y): 1.79
• Revenue Growth: 6.23%
• EPS Growth: 283.88%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.11
• Shares Outstanding: 20,336,184
• 10 Day Avg. Volume: 123,900
• 30 Day Avg. Volume: 111,089
• PEG Ratio: 0.46
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 1.33
• P/FCF Ratio: 68.45
• Enterprise Value/Market Cap: 1.38
• Enterprise Value/Revenue: 1.71
• Enterprise Value/Gross Profit: 3.08
• Enterprise Value/Ebitda: 9.85
• 1Y Price Target: $13.67
• Price Target Upside: 42.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.38
• Revenue Forecast (FY): $153.84M

• Rating: 68 Neutral
• Price Target: $10.00 ▲(4.17% Upside)

InfuSystem Holdings shows strong financial performance and strategic growth initiatives, particularly in Oncology and Wound Care. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. Recent corporate events, including CMS approval, provide a positive outlook for future growth.

Positive Factors

CMS Approval for Infusion Pumps

CMS approval enhances InfuSystem's market position in non-opioid pain management, likely boosting revenue and adoption of its products.

Strong Revenue Growth

Consistent revenue growth indicates robust market demand and effective business strategies, supporting long-term expansion.

Strategic Partnerships

Strategic partnerships expand market reach and service offerings, strengthening competitive advantage and revenue potential.

Negative Factors

Biomedical Services Revenue Decline

Revenue decline in biomedical services could impact overall financial performance, necessitating adjustments in business strategy.

Negative Free Cash Flow Growth

Negative free cash flow growth may limit the company's ability to invest in growth opportunities and manage financial obligations.

Device Solutions Revenue Decrease

A decrease in Device Solutions revenue suggests potential challenges in product sales, impacting overall revenue growth.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

How the Company Makes Money

InfuSystem generates revenue through several key streams: primarily by providing outpatient infusion therapy services, which includes the rental and management of infusion pumps and the associated supplies necessary for treatment. The company also earns revenue from the sale of infusion devices and supplies directly to healthcare providers and patients. Additionally, InfuSystem's revenue model benefits from long-term contracts with hospitals and healthcare facilities, creating stable income sources. Strategic partnerships with pharmaceutical companies and healthcare organizations further enhance its market reach and service offerings, contributing to the overall earnings of the company.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings demonstrates strong revenue growth and improved leverage, positioning it well for future expansion. However, profitability margins and free cash flow growth present areas for improvement to ensure sustainable financial health.

Income Statement

InfuSystem Holdings shows a strong revenue growth rate of 83.5% in TTM, indicating robust expansion. Gross profit margin improved to 55.35%, reflecting efficient cost management. However, the net profit margin remains modest at 3.92%, suggesting room for profitability enhancement.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.45, indicating a reduction in leverage and a stronger equity position. Return on equity is at 9.92%, showing a decent return on shareholders' investments. The equity ratio is stable, suggesting a balanced asset structure.

Cash Flow

Operating cash flow is strong with a coverage ratio of 1.35, indicating good cash generation relative to net income. However, free cash flow growth is negative at -6.58%, pointing to potential challenges in maintaining cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	141.05M	134.86M	125.78M	109.91M	102.38M	97.39M
Gross Profit	78.08M	70.40M	63.11M	60.56M	58.54M	58.76M
EBITDA	24.44M	20.03M	16.53M	14.89M	17.26M	22.82M
Net Income	5.52M	2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet
Total Assets	98.88M	103.61M	102.92M	99.39M	97.59M	96.99M
Cash, Cash Equivalents and Short-Term Investments	955.00K	527.00K	231.00K	165.00K	186.00K	9.65M
Total Debt	24.69M	28.42M	34.90M	36.92M	36.77M	42.66M
Total Liabilities	43.41M	46.09M	50.61M	51.38M	49.31M	56.24M
Stockholders Equity	55.47M	57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow
Free Cash Flow	18.65M	2.63M	106.00K	2.44M	1.66M	3.37M
Operating Cash Flow	25.21M	20.46M	11.22M	17.52M	18.32M	20.28M
Investing Cash Flow	-7.87M	-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
Financing Cash Flow	-16.77M	-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Neutral. The current price of 9.6 is above the 20-day moving average (MA) of 8.89, above the 50-day MA of 9.23, and above the 200-day MA of 7.88, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 46.46 is Neutral, neither overbought nor oversold. The STOCH value of 57.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$174.89M	33.56	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$193.09M	17.05	9.59%	2.15%	-12.35%	-17.20%
KRMD	59 Neutral	$262.65M	-68.28	-21.71%	―	22.12%	69.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	47 Neutral	$196.55M	-3.32	-15.30%	―	-43.95%	-620.21%
SMTI	42 Neutral	$212.40M	-5.26	-27.19%	―	30.55%	-340.19%

InfuSystem Holdings Corporate Events

InfuSystem Holdings Gains CMS Approval for Infusion Pumps

On December 10, 2025, InfuSystem Holdings announced that the Centers for Medicare and Medicaid Services (CMS) has included two of its electronic infusion pumps in the list of qualifying products for separate payment under the NOPAIN Act, effective January 1, 2026. This decision is part of CMS’s broader strategy to combat the opioid crisis by promoting non-opioid pain management alternatives, potentially boosting InfuSystem’s Pain Management business by encouraging healthcare providers to adopt these non-opioid treatments.

The most recent analyst rating on (INFU) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Announces Regulation FD Disclosure

InfuSystem Holdings reported six consecutive years of record revenue, with a compound annual growth rate of 12% in revenue and 11% in adjusted EBITDA. The company announced various strategic partnerships and distribution agreements in recent years, enhancing its market position and expanding its service offerings in areas like wound care and biomedical services.

The most recent analyst rating on (INFU) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings to Attend Craig-Hallum Conference

InfuSystem Holdings announced that its President and CEO, Carrie Lachance, and CFO, Barry Steele, will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York City. This participation highlights the company’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market positioning and investor relations positively.

The most recent analyst rating on (INFU) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings to Announce Q3 2025 Results

InfuSystem Holdings, Inc. announced that it will release its third-quarter 2025 financial results on November 4, 2025, before the market opens. The company will also hold a conference call on the same day to discuss the financial results, providing stakeholders with insights into its performance and future outlook.

The most recent analyst rating on (INFU) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.